-
Glaukos Way Ahead Of The Glaucoma Competition
Friday, September 23, 2016 - 1:53pm | 424Read More...Cantor Fitzgerald reiterated its Buy rating and $41 price target on Glaukos Corp (NYSE: GKOS) after the company reported efficacy data from a three-year international study of two iStent devices in over 100 devices. Elaborating on the trial and results, the firm's analyst Elemer Piros noted that...
-
263% Upside Seen In Abeona Therapeutics
Wednesday, September 21, 2016 - 1:00pm | 241Read More...Cantor Fitzgerald reiterated its Buy rating and $21 price target on the shares of Abeona Therapeutics Inc (NASDAQ: ABEO). The catalyst being the company's announcement of licensing of a next generation gene vector delivery system along with a clinical trial-ready therapy for Batten disease...
-
Cantor Fitzgerald Never Gave Up On Tobira Therapeutics
Wednesday, September 21, 2016 - 10:10am | 317Read More...Allergan plc Ordinary Shares (NYSE: AGN) has announced the acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA) for a premium of more than 400 percent. Cantor Fitzgerald’s Elemer Piros downgraded the rating on Tobira from Buy to Hold, while raising the price target from $19 to $42....
-
Cantor Lifts Aerie's Price Target To $50 Following 'Rock Solid Phase 3 Roclatan Results'
Thursday, September 15, 2016 - 12:11pm | 326Read More...Shares of Aerie Pharmaceuticals Inc (NASDAQ: AERI) soared higher by more than 50 percent Thursday after the company reported Phase 3 data involving Roclatan which met its primary efficacy endpoint. In a report, Dr. Elemer Piros of Cantor Fitzgerald suggested that the data was "impeccable...
-
Intercept Shares Turn Negative Following Mid-Day Sell Rating From Cantor
Wednesday, July 6, 2016 - 3:57pm | 177Read More...Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares took an intra-day turn lower Wednesday after Cantor Fitzgerald issued a concerning mid-day note on the name. Shares had been trading in positive territory for a couple hours ahead of the new sell-side recommendation; the stock last traded down...
-
Cantor Fitzgerald Assumes Coverage Of Glaukos Corp With Buy, $35TP
Friday, June 3, 2016 - 9:47am | 347Read More...Cantor Fitzgerald has assumed coverage of Glaukos Corp (NYSE: GKOS) with a Buy rating and $35 price target on the market potential for its iStent device in Glaucoma treatment. "Through innovation, we believe the company can not only maintain but likely expand its leading position,"...
-
Cantor Fitzgerald Initiates Dimension At Buy: 'Best In Class Therapies'
Friday, June 3, 2016 - 9:23am | 127Read More...Canton Fitzgerald's Elemer Piros initiated Dimension Therapeutics Inc (NASDAQ: DMTX) at Buy with a $32.00 price objective. "Dimension has assembled a suite of potentially best-in-class liver-targeted gene therapies" with a $275-million-dollar licensing agreement with Bayer...
-
Cantor Fitzgerald Sees 81% Upside In Spark Therapeutics; Initiating with A Buy
Friday, June 3, 2016 - 9:18am | 340Read More...Cantor Fitzgerald said Spark Therapeutics Inc (NASDAQ: ONCE) could become the first company with an approved gene therapy product in the United States. The brokerage initiated the company with a Buy rating and $100 price target. Cantor Fitzgerald's target price implies a potential upside of...
-
Cantor Initiates Aerie Pharma At Buy: 'Wouldn't Be Surprised If Aerie Became Takeover Candidate'
Friday, June 3, 2016 - 9:10am | 161Read More...Cantor Fitzgerald's Elemer Piros initiated Aerie Pharmaceuticals Inc (NASDAQ: AERI) at Buy with a price target of $44. "Aerie could dominate the glaucoma market with drugs that have novel mechanisms of action," said Piros. Glaucoma is a popular disease in the United States, but...
-
Cantor Fitzgerald Starts GW Pharmaceuticals At Buy, Positive On Potential For Epidiolex
Thursday, June 2, 2016 - 5:31pm | 237Read More...Cantor Fitzgerald's Elemer Piros is positive on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH)'s technology value of its drug portfolio and estimated year-end 2016 cash position. He has a bullish view on the potential for Epidiolex following the published anecdotal evidence on the impact to...
-
Bluebird Bio Initiated Hold At Cantor Fitzgerald, Decides To Await Additional Data
Thursday, June 2, 2016 - 5:19pm | 184Read More...Following a killer day for bluebird bio inc (NASDAQ: BLUE), Cantor Fitzgerald extinguished the flames with a Hold initiation and a price target of $42. Year-to-date, bluebird bio is down over 25 percent. Analyst Elemer Piros remains indifferent on the company ahead of the expected December 2016...
-
Roth's Piros: Galectin Therapeutics Shares Can Quadruple In Next 12 Months
Wednesday, March 9, 2016 - 4:00pm | 449Read More...Shares of Galectin Therapeutics Inc (NASDAQ: GALT) could reach $6 in the next 12 months, according to Roth Capital's Elemer Piros who initiated the stock with a Buy rating. Galectin is developing a drug that could prevent and reverse fibrosis in nonalcoholic steatohepatitis (NASH) patients...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
-
Roth Reinstates Coverage On Bluebird Bio, Sees Massive 50% Upside
Thursday, December 3, 2015 - 9:51am | 336Read More...bluebird bio Inc (NASDAQ: BLUE) shares 39 percent year-to-date, even after trading above $140 on September 18. Roth Capital Partners’ Elemer Piros reinitiated coverage of the company with a Buy rating and a price target of $121. Piros said that there is upside from sickle cell...
-
Time To Buy GW Pharma, Roth Capital Says
Monday, November 30, 2015 - 2:38pm | 336Read More...GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down 20 percent in the last three months, and are trading significantly below their 52-week high of $133.98. Roth Capital Partners’ Elemer Piros reinitiated coverage of the company with a Buy rating and a price target of $130....
